BioAge Labs, Inc. BIOA
7.05
(0.16)
(2.22%)
as of 25 Sep
- Market cap
- $337.4M
- P/E
- 0.0×
Follow BIOA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+7 more TTM periods Free account |
(25.64%) | (27.09%) | (25.98%) | (28.21%) | |
| (23.59%) | (24.68%) | (24.26%) | (26.27%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (118.25%) | |
Return on Tangible Assets |
(28.35%) | (30.12%) | (23.84%) | (30.25%) | |
Average Days of Receivables |
0.00 | 31.20 | 25.09 | 22.03 | |
Free Cash Flow per Share |
(1.65) | (6.60) | (5.73) | (5.42) | |
Free Cash Flow |
(59.15) | (237.09) | (243.38) | (242.84) | |
Capital Expenditures |
(0.63) | (155.47) | (155.07) | (155.23) | |
Piotroski F-Score |
3.00 | 0.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(10.31%) | (14.69%) | (11.57%) | (12.63%) | |
Accounts Receivable Turnover |
— | 0.00 | 19.28 | 16.86 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 822.30% | 807.16% | 847.78% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 309.16% | 278.77% | 278.49% | |
Share Based Compensation of Revenue |
0.00% | 129.97% | 126.00% | 135.57% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 1.01 | 0.98 | 0.93 | |
Depreciation/Fixed assets |
0.20 | 0.22 | 0.21 | 0.21 | |
Capex/Depreciation |
(3.31) | (729.89) | (648.81) | (618.47) | |
Revenue per Share |
0.00 | 0.25 | 0.24 | 0.23 | |
Operating CF per Share |
(1.63) | (2.27) | (2.08) | (1.95) | |
Capex per Share |
(0.02) | (4.33) | (3.65) | (3.46) | |
Capex to Sales |
0.00 | 17.28 | 15.03 | 14.99 | |
Net Profit Margin |
0.00% | (896.11%) | (871.75%) | (912.25%) |
Columns are period end dates